OxThera is a biopharmaceutical company dedicated to developing microbial-based drug products for the treatment of hyperoxaluria, a rare kidney disease
OxThera is a biopharmaceutical company dedicated to developing microbial-based drug products for the treatment of hyperoxaluria, a rare kidney disease. Their lead product, Oxabact, is an orally administered treatment that promotes the secretion of oxalate from the plasma into the gut, thereby reducing the burden on the kidneys.